The study reached 170 confirmed cases of #COVID19, with the #vaccine candidate BNT162b2 demonstrating 95% efficacy beginning 28 days after the first dose.— Pfizer Inc. (@pfizer) November 18, 2020
The study reached 170 confirmed cases of #COVID19, with the #vaccine candidate BNT162b2 demonstrating 95% efficacy beginning 28 days after the first dose.